BACKGROUND:Patients with acute rhinosinusitis are frequently encountered in primary care. Although corticosteroids are being increasingly used for symptom control, evidence supporting their use is inconclusive. We conducted a randomized controlled trial to examine the effectiveness of systemic corticosteroid monotherapy for clinically diagnosed, uncomplicated acute rhinosinusitis. METHODS: We conducted a block-randomized, double-blind, placebo-controlled clinical trial at 54 primary care practices (68 family physicians) in the Netherlands between Dec. 30, 2008, and Apr. 28, 2011. Adult patients with clinically diagnosed acute rhinosinusitis were randomly assigned to receive either prednisolone 30 mg/d or placebo for 7 days and asked to complete a symptom diary for 14 days. The primary outcome measure was the proportion of patients with resolution of facial pain or pressure on day 7. RESULTS: Of the 185 patients included in the trial (93 in the treatment group, 92 in the placebo group), 2 withdrew from the study and 9 were excluded from the primary analysis because of incomplete symptom reporting. The remaining 174 patients (88 in the treatment group, 86 in the placebo group) were included in the intention-to-treat analysis. The proportions of patients with resolution of facial pain or pressure on day 7 were 62.5% (55/88) in the prednisolone group and 55.8% (48/86) in the placebo group (absolute risk difference 6.7%, 95% confidence interval -7.9% to 21.2%). The groups were similar with regard to the decrease over time in the proportion of patients with total symptoms (combined symptoms of runny nose, postnasal discharge, nasal congestion, cough and facial pain) and health-related quality of life. Adverse events were mild and did not differ significantly between the groups. INTERPRETATION:Systemic corticosteroid monotherapy had no clinically relevant beneficial effects among patients with clinically diagnosed acute rhinosinusitis. Netherlands Trial Register registration no. 1295 (www.trialregister.nl/trialreg/index.asp).
RCT Entities:
BACKGROUND:Patients with acute rhinosinusitis are frequently encountered in primary care. Although corticosteroids are being increasingly used for symptom control, evidence supporting their use is inconclusive. We conducted a randomized controlled trial to examine the effectiveness of systemic corticosteroid monotherapy for clinically diagnosed, uncomplicated acute rhinosinusitis. METHODS: We conducted a block-randomized, double-blind, placebo-controlled clinical trial at 54 primary care practices (68 family physicians) in the Netherlands between Dec. 30, 2008, and Apr. 28, 2011. Adult patients with clinically diagnosed acute rhinosinusitis were randomly assigned to receive either prednisolone 30 mg/d or placebo for 7 days and asked to complete a symptom diary for 14 days. The primary outcome measure was the proportion of patients with resolution of facial pain or pressure on day 7. RESULTS: Of the 185 patients included in the trial (93 in the treatment group, 92 in the placebo group), 2 withdrew from the study and 9 were excluded from the primary analysis because of incomplete symptom reporting. The remaining 174 patients (88 in the treatment group, 86 in the placebo group) were included in the intention-to-treat analysis. The proportions of patients with resolution of facial pain or pressure on day 7 were 62.5% (55/88) in the prednisolone group and 55.8% (48/86) in the placebo group (absolute risk difference 6.7%, 95% confidence interval -7.9% to 21.2%). The groups were similar with regard to the decrease over time in the proportion of patients with total symptoms (combined symptoms of runny nose, postnasal discharge, nasal congestion, cough and facial pain) and health-related quality of life. Adverse events were mild and did not differ significantly between the groups. INTERPRETATION: Systemic corticosteroid monotherapy had no clinically relevant beneficial effects among patients with clinically diagnosed acute rhinosinusitis. Netherlands Trial Register registration no. 1295 (www.trialregister.nl/trialreg/index.asp).
Authors: Eli O Meltzer; Daniel L Hamilos; James A Hadley; Donald C Lanza; Bradley F Marple; Richard A Nicklas; Claus Bachert; James Baraniuk; Fuad M Baroody; Michael S Benninger; Itzhak Brook; Badrul A Chowdhury; Howard M Druce; Stephen Durham; Berrylin Ferguson; Jack M Gwaltney; Michael Kaliner; David W Kennedy; Valerie Lund; Robert Naclerio; Ruby Pawankar; Jay F Piccirillo; Patricia Rohane; Ronald Simon; Raymond G Slavin; Alkis Togias; Ellen R Wald; S James Zinreich Journal: J Allergy Clin Immunol Date: 2004-12 Impact factor: 10.793
Authors: M I Asher; U Keil; H R Anderson; R Beasley; J Crane; F Martinez; E A Mitchell; N Pearce; B Sibbald; A W Stewart Journal: Eur Respir J Date: 1995-03 Impact factor: 16.671
Authors: Gail Nicola Hayward; Alastair D Hay; Michael V Moore; Sena Jawad; Nicola Williams; Merryn Voysey; Johanna Cook; Julie Allen; Matthew Thompson; Paul Little; Rafael Perera; Jane Wolstenholme; Kim Harman; Carl Heneghan Journal: JAMA Date: 2017-04-18 Impact factor: 56.272
Authors: Alastair D Hay; Paul Little; Anthony Harnden; Matthew Thompson; Kay Wang; Denise Kendrick; Elizabeth Orton; Sara T Brookes; Grace J Young; Margaret May; Sandra Hollinghurst; Fran E Carroll; Harriet Downing; David Timmins; Natasher Lafond; Magdy El-Gohary; Michael Moore Journal: JAMA Date: 2017-08-22 Impact factor: 56.272
Authors: Rick T van Uum; Roderick P Venekamp; Alies Sjoukes; Alma C van de Pol; G Ardine de Wit; Anne G M Schilder; Roger A M J Damoiseaux Journal: Trials Date: 2018-09-17 Impact factor: 2.279
Authors: Valerie Hox; Evelijn Lourijsen; Arnout Jordens; Kristian Aasbjerg; Ioana Agache; Isam Alobid; Claus Bachert; Koen Boussery; Paloma Campo; Wytske Fokkens; Peter Hellings; Claire Hopkins; Ludger Klimek; Mika Mäkelä; Ralph Mösges; Joaquim Mullol; Laura Pujols; Carmen Rondon; Michael Rudenko; Sanna Toppila-Salmi; Glenis Scadding; Sophie Scheire; Peter-Valentin Tomazic; Thibaut Van Zele; Martin Wagemann; Job F M van Boven; Philippe Gevaert Journal: Clin Transl Allergy Date: 2020-01-03 Impact factor: 5.871